Yang Ping carefully analyzed the structure of the K Factor, then compared it with the nutrient solution used to cultivate the tumor at the ti. Using a structural comparison analysis thod, he initially speculated that the possibility of the K Factor being generated by a chemical reaction between the components of the nutrient solution was very small.
Based on the most basic atomic conservation in chemical reactions, although there is so overlap between the atoms of the K Factor and those of the nutrient solution, many basic structures and groups have little overlap with the nutrients, making significant chemical conversion unlikely.
Yang Ping also theoretically speculated on several other possible causes, all of which seed improbable. Ultimately, he inclined towards the belief that the K Factor was produced by the tumor cells themselves.
After considering the most fundantal principles, Yang Ping reached a simple conclusion: the K Factor is not a simple chemical substance but a complex protein structure, sothing that could absolutely not be completed by a simple, random chemical reaction. Even if such chemical reactions could complete it, they would require an extrely long ti and countless chemical reactions.
Every chemical reaction is a coincidence, and chaining these coincidences together results in such a small probability, one that approaches zero.
Stacking possibilities that approach zero together to eventually form a greater possibility takes a long ti, going through trial and error, similar to the formation of life proteins which required billions of years of coincidences to accumulate.
Now that Yang Ping has concluded that the tumor cells secrete the K Factor themselves, the next step is to arrange whether the process of tumor cells secreting the K Factor can be replicated, and then study it—this is the key.
To replicate the process at that ti, it is necessary to analyze the entire experintal environnt at that ti, as the condition accidentally overlooked might be exactly the most crucial one.
Coming out of the System Space, Yang Ping took the opportunity after work to visit the elderly cadres having dical exams at the Overseas Chinese Building, especially those who had undergone surgery. He took the chance to chat with them, learning from them the spirit of relentless struggle, that unique confidence and courage, and the perseverance to move forward in difficult circumstances.
These elderly comrades also enjoyed chatting with Yang Ping, holding his hand and talking non-stop. The ones who had undergone surgery kept asking daily when they could be discharged—they probably felt uncomfortable staying in the hospital all day long.
Upon leaving the Overseas Chinese Building, Yang Ping received a call from Dean Xia, who ntioned that a leader from Beijing had specifically co to visit the old comrades undergoing dical examinations. He had visited them that morning and stayed there hoping to et Yang Ping.
This leader is in charge of the national healthcare industry. Since Sanbo Hospital ca under direct managent from Beijing, he had not t with Yang Ping yet, always reconnecting through Dean Xia.
It wasn’t that he was too busy to et Yang Ping, but rather he avoided eting him as much as possible to maintain Yang Ping’s previous free and independent work environnt, preventing him from feeling controlled.
This ti, the leader considered it an "accidental" opportunity to et Yang Ping. Dean Xia, understanding the leader’s consistent thoughts, felt quite touched, seeing that the higher-ups valued Yang Ping greatly. Otherwise, they wouldn’t have upgraded Sanbo Hospital to co directly under the managent of Beijing, nor would they be so considerate of his feelings.
In the leader’s view, a doctor as talented as Yang Ping is extrely rare, deserving an environnt he likes, and shouldn’t be disturbed—no matter how little.
"An informal eting, just like our usual chats, everyone sits down to drink tea and have a casual conversation, and I’ll be by your side the whole ti." Dean Xia, familiar with Yang Ping’s dislike of protocol, explained as he feared Yang Ping might refuse.
"Alright!" Yang Ping agreed. After all, he should give so respect, not to ntion, the leader’s support for him and Sanbo Hospital had always been substantial. Just for this reason alone, he ought to et the leader and express his thanks.
The eting wasn’t as formal as expected—quite ordinary, in fact, held in Dean Xia’s office. Dean Xia accompanied them throughout, and the leader was very friendly, chatting casually with Yang Ping, with no trace of a hierarchical relationship.
During the conversation, the leader expressed concerns over so key foundational technologies in the pharmaceutical industry, noting that many crucial technologies are currently in a state of extre backwardness. Due to the particularity of the pharmaceutical industry, its developnt is slower than other industries.
Among them, the leader ntioned a core technology related to vaccines—adjuvants. Most of this key technology, critical to national welfare and people’s livelihoods, relies on imports, and the core technology is entirely in others’ hands. Any disruption could affect the health of many people.
Vaccines are not unfamiliar, but few people know about vaccine adjuvants. An adjuvant is a substance added to vaccines to enhance the immunogenicity of the vaccine antigen. From its na, an adjuvant seems rely like a seasoning in vaccine production, akin to cooking ingredients, seemingly inconsequential, but in reality, adjuvants play a critical role in vaccines.
For example, recombinant protein vaccines only include the immune-recognizable part of the pathogen leading to protection, thereby increasing the vaccine’s purity while reducing side effects—but at the sa ti, the vaccine’s immunogenicity is also reduced.
To resolve this contradiction, the only current thod is to add adjuvants to enhance the vaccine’s immunogenicity.
Therefore, adjuvants are indispensable and extrely important. Without them, vaccines cannot be produced.
International pharmaceutical giants place extraordinary importance on adjuvants. Many examples show how they enhance their vaccine products’ effectiveness with superior adjuvants to outperform competitors.
User Comments
0 comments from readers